ASX - By Stock
|
LRK |
Re:
Ann: FY22 Results Presentation
|
|
All4Info
|
25 |
11K |
6 |
31/08/22 |
31/08/22 |
ASX - By Stock
|
25
|
11K
|
6
|
|
ASX - By Stock
|
LRK |
Re:
Ann: FY22 Results Presentation
|
|
All4Info
|
25 |
11K |
3 |
30/08/22 |
30/08/22 |
ASX - By Stock
|
25
|
11K
|
3
|
|
ASX - By Stock
|
LRK |
Re:
Ann: FY22 Results Webinar
|
|
All4Info
|
5 |
3.2K |
5 |
26/08/22 |
26/08/22 |
ASX - By Stock
|
5
|
3.2K
|
5
|
|
ASX - By Stock
|
LRK |
Re:
Ann: June 2022 Quarterly Update and Appendix 4C
|
|
All4Info
|
11 |
6.6K |
2 |
26/07/22 |
26/07/22 |
ASX - By Stock
|
11
|
6.6K
|
2
|
|
ASX - By Stock
|
LRK |
Re:
Ann: June 2022 Quarterly Update and Appendix 4C
|
|
All4Info
|
11 |
6.6K |
2 |
26/07/22 |
26/07/22 |
ASX - By Stock
|
11
|
6.6K
|
2
|
|
ASX - By Stock
|
NTI |
Re:
NTI Chart
|
|
All4Info
|
283 |
117K |
5 |
26/07/22 |
26/07/22 |
ASX - By Stock
|
283
|
117K
|
5
|
|
ASX - By Stock
|
LRK |
Re:
Ann: June 2022 Quarterly Update and Appendix 4C
|
|
All4Info
|
11 |
6.6K |
3 |
26/07/22 |
26/07/22 |
ASX - By Stock
|
11
|
6.6K
|
3
|
|
ASX - By Stock
|
LRK |
Re:
Ann: June 2022 Quarterly Update and Appendix 4C
|
|
All4Info
|
11 |
6.6K |
9 |
26/07/22 |
26/07/22 |
ASX - By Stock
|
11
|
6.6K
|
9
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Q&A on NTI164 Breakthrough Clinical Trial Results in ASD
|
|
All4Info
|
2 |
1.2K |
7 |
22/07/22 |
22/07/22 |
ASX - By Stock
|
2
|
1.2K
|
7
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
7 |
21/07/22 |
21/07/22 |
ASX - By Stock
|
59
|
38K
|
7
|
|
ASX - By Stock
|
NTI |
Re:
The market has it wrong
|
|
All4Info
|
15 |
7.2K |
5 |
15/07/22 |
15/07/22 |
ASX - By Stock
|
15
|
7.2K
|
5
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
0 |
12/07/22 |
12/07/22 |
ASX - By Stock
|
59
|
38K
|
0
|
|
ASX - By Stock
|
NTI |
Re:
Ann: BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
|
|
All4Info
|
33 |
11K |
2 |
12/07/22 |
12/07/22 |
ASX - By Stock
|
33
|
11K
|
2
|
|
ASX - By Stock
|
NTI |
Re:
Ann: BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
|
|
All4Info
|
33 |
11K |
7 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
33
|
11K
|
7
|
|
ASX - By Stock
|
NTI |
Re:
Ann: BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
|
|
All4Info
|
33 |
11K |
3 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
33
|
11K
|
3
|
|
ASX - By Stock
|
NTI |
Re:
Ann: BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
|
|
All4Info
|
33 |
11K |
3 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
33
|
11K
|
3
|
|
ASX - By Stock
|
NTI |
Re:
Ann: BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
|
|
All4Info
|
33 |
11K |
4 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
33
|
11K
|
4
|
|
ASX - By Stock
|
NTI |
Re:
Ann: BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
|
|
All4Info
|
33 |
11K |
8 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
33
|
11K
|
8
|
|
ASX - By Stock
|
LOM |
Re:
Ann: Additional Priority Kimberlites Identified at Lulo
|
|
All4Info
|
133 |
34K |
13 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
133
|
34K
|
13
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Extension to Voluntary Suspension
|
|
All4Info
|
9 |
2.6K |
5 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
9
|
2.6K
|
5
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Extension to Voluntary Suspension
|
|
All4Info
|
9 |
2.6K |
2 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
9
|
2.6K
|
2
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Suspension from Official Quotation
|
|
All4Info
|
5 |
2.0K |
3 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
5
|
2.0K
|
3
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Trading Halt
|
|
All4Info
|
8 |
3.3K |
4 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
8
|
3.3K
|
4
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
7 |
05/07/22 |
05/07/22 |
ASX - By Stock
|
59
|
38K
|
7
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Trading Halt
|
|
All4Info
|
8 |
3.3K |
7 |
04/07/22 |
04/07/22 |
ASX - By Stock
|
8
|
3.3K
|
7
|
|
ASX - By Stock
|
NTI |
Re:
NTI Chart
|
|
All4Info
|
283 |
117K |
4 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
283
|
117K
|
4
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Cholesterol-Lowering Program Update
|
|
All4Info
|
5 |
2.9K |
9 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
5
|
2.9K
|
9
|
|
ASX - By Stock
|
NYR |
Re:
News: NYR Zinc stocks slide as shortages in Europe persist
|
|
All4Info
|
20 |
6.6K |
4 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
20
|
6.6K
|
4
|
|
ASX - By Stock
|
LOM |
Re:
Ann: Additional Priority Kimberlites Identified at Lulo
|
|
All4Info
|
133 |
34K |
6 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
133
|
34K
|
6
|
|
ASX - By Stock
|
LOM |
Re:
Ann: Additional Priority Kimberlites Identified at Lulo
|
|
All4Info
|
133 |
34K |
3 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
133
|
34K
|
3
|
|
ASX - By Stock
|
NTI |
Re:
NTI Chart
|
|
All4Info
|
283 |
117K |
5 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
283
|
117K
|
5
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
10 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
59
|
38K
|
10
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Preclinical Success with Targeted Combination Therapies
|
|
All4Info
|
20 |
8.7K |
2 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
20
|
8.7K
|
2
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Preclinical Success with Targeted Combination Therapies
|
|
All4Info
|
20 |
8.7K |
1 |
13/06/22 |
13/06/22 |
ASX - By Stock
|
20
|
8.7K
|
1
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Preclinical Success with Targeted Combination Therapies
|
|
All4Info
|
20 |
8.7K |
0 |
10/06/22 |
10/06/22 |
ASX - By Stock
|
20
|
8.7K
|
0
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Preclinical Success with Targeted Combination Therapies
|
|
All4Info
|
20 |
8.7K |
3 |
10/06/22 |
10/06/22 |
ASX - By Stock
|
20
|
8.7K
|
3
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Corporate Presentation
|
|
All4Info
|
4 |
2.3K |
4 |
10/06/22 |
10/06/22 |
ASX - By Stock
|
4
|
2.3K
|
4
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Investor Webinar Presentation
|
|
All4Info
|
6 |
1.8K |
0 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
6
|
1.8K
|
0
|
|
ASX - By Stock
|
NTI |
Re:
NTI Chart
|
|
All4Info
|
283 |
117K |
2 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
283
|
117K
|
2
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Investor Webinar Presentation
|
|
All4Info
|
6 |
1.8K |
1 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
6
|
1.8K
|
1
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Investor Webinar Presentation
|
|
All4Info
|
6 |
1.8K |
0 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
6
|
1.8K
|
0
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
5 |
02/06/22 |
02/06/22 |
ASX - By Stock
|
59
|
38K
|
5
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
9 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
59
|
38K
|
9
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
4 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
59
|
38K
|
4
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
3 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
59
|
38K
|
3
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
3 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
59
|
38K
|
3
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
0 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
59
|
38K
|
0
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
7 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
59
|
38K
|
7
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Key Development in Current Paediatric ASD Study
|
|
All4Info
|
10 |
3.6K |
2 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
10
|
3.6K
|
2
|
|
ASX - By Stock
|
LRK |
Re:
Valuation of Lark and stock-holdings
|
|
All4Info
|
59 |
38K |
3 |
20/05/22 |
20/05/22 |
ASX - By Stock
|
59
|
38K
|
3
|
|